Results 111 to 120 of about 2,555,654 (307)

The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study

open access: yesBMC Cancer, 2018
Background Chronic myeloid leukemia is associated with a BCR/ABL oncoprotein inhibited by imatinib mesylate, the first tyrosine kinase inhibitor. Although experimental studies have clearly demonstrated the efficacy of imatinib, up-to-date data on its ...
Enza Di Felice   +7 more
doaj   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm   +2 more
wiley   +1 more source

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

open access: yesHaematologica, 2012
Background Protein phosphatase 2A is a novel potential therapeutic target in several types of chronic and acute leukemia, and its inhibition is a common event in acute myeloid leukemia.
Ion Cristóbal   +6 more
doaj   +1 more source

The synergistic impact of granulocytic myeloid‐derived suppressor cells and innate lymphoid cells in systemic sclerosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by immune dysregulation and fibrosis, with myeloid‐derived suppressor cells (MDSCs) emerging as important regulators of immune responses. However, the role of MDSCs in SSc‐associated fibrosis and their interactions with other immune cell populations remain poorly ...
Stefanie Weber   +15 more
wiley   +1 more source

Avaliação de parâmetros laboratoriais e clínicos de pacientes portadores de leucemia mielóide crônica submetidos ao tratamento com mesilato de imatinibe e sua relação com alterações observadas no estroma da medula óssea Correlation between laboratory and clinical parameters of chronic myeloid leukemia patients treated with imatinib mesylate and its relationship with stromal changes observed in bone marrow biopsy [PDF]

open access: yes, 2007
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-graduação em FarmáciaA leucemia mieloide cronica (LMC) e uma doenca mieloproliferativa clonal, responsavel por 14% de todos os casos de ...
Caroline R. de Jesus   +1 more
core   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Profile of imatinib in pediatric leukemia

open access: yesPediatric Health, Medicine and Therapeutics, 2014
Michael J BurkeDepartment of Pediatrics, Division of Hematology/Oncology/Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI, USAAbstract: Using targeted therapy for treatment of cancer has become the paradigm to which clinical ...
Burke MJ
doaj  

Regulatory harmonization: Evolution, globalization and future directions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm   +2 more
wiley   +1 more source

Oral Azacitidine Maintenance After CPX‐351 in Transplant‐Ineligible Patients With Therapy‐Related or Myelodysplasia‐Related Acute Myeloid Leukemia

open access: yes
American Journal of Hematology, EarlyView.
Caroline Fileni   +18 more
wiley   +1 more source

Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model‐based simulation of the positioning imatinib for pulmonary arterial hypertension trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
ABSTRACT Aims Imatinib improves hemodynamics in pulmonary arterial hypertension (PAH), but dose‐dependent toxicity has limited its clinical development. We aimed to quantify the dose–efficacy–toxicity relationship and evaluate alternative dosing strategies using data from the PIPAH trial.
Medhat M. Said   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy